INTRODUCTION
Homocysteine (Hcy) is a sulphur amino acid synthesized during the metabolic conversion of methionine to cysteine. In the trans-sulphuration pathway, homocysteine is converted to cystathionine, but it can also be remethylated via the folate cycle. This pathway requires the methionine synthase enzyme and cobalamin (vitamin B12) as well as the N 5 ,N 10 -methylenetetrahydrofolate reductase enzyme (MTHFR) and folic acid (FA), which enters the cycle as tetrahydrofolate [1] . Normal Hcy levels oscillate between 5 and 15 μM. Higher concentrations are considered to indicate a metabolic disorder called hyperhomocysteinemia (HHcy) [1] . While severe HHcy (over 100 μM) is a rare condition, 5 to 7% of the general population suffers from mild to moderate hyperhomocysteinemia (15 to 100 μM). Numerous epidemiological and clinical studies have indicated an association between elevated plasma Hcy concentrations and vascular diseases, including coronary artery disease (CAD), stroke, myocardial infarction (MI) and venous thromboembolism [2] [3] [4] . Plasma Hcy levels are determined by demographic, environmental and genetic factors. Normal homocysteine metabolism is dependent on an adequate supply of three dietary vitamins: FA, vitamin B12 and vitamin B6. Thus, a nutritional deficiency of these vitamins may cause moderate HHcy [3, 5] . Several genetically inherited enzyme mutations responsible for elevated homocysteine levels have been described, of which probably the most common one is the cytosine to thymine transition at nucleotide 677 (677C>T) of the MTHFR enzyme [5] . This polymorphism decreases MTHFR activity, which is associated with a decrease in the redundancy ratio of 5,10-MTHF to 5-MTHF and an increase in the level of 5,10-MTHF bioavailability for the oxidation of folate to formyl forms [6] . Endothelial dysfunction, i.e. impairment of the homeostatic properties of the vascular endothelium, leads to adverse cardiovascular outcomes. The hyperhomocysteinemic state causes endothelial dysfunction in humans, animals and in the experimental in vitro model [7] [8] [9] . Endothelial cell activation followed by apoptosis is also related to endothelial dysfunction. In this state, endothelial cells release qualitatively and quantitatively diverse small membrane vesicles called microparticles (MPs), which vary in diameter between 0.1 and 1.5 µm.
MPs are used as a marker of endothelial dysfunction and the procoagulation state [10, 11] . MPs may harbor a diversity of cell surface proteins, among them CD31 (PECAM-1, platelet endothelial cell adhesion molecule-1), which is a selective marker of matured and progenitor endothelial cells [12] . Additionally, phosphatidylserine, which is specifically bound to annexin V, is exposed on the endothelial MP surface [12] , and annexin V-positive MPs are observed during apoptosis [10] . There is little evidence that homocysteine influences MP formation. In patients with chronic renal failure, both dialyzed and undialyzed, the elevation of apoptotic, annexin V-positive, endothelial MPs was observed [13] . However, the role of p-cresol and indoxyl sulfate rather than Hcy was documented [13, 14] .
In our study, we tested the hypothesis that moderate concentrations of homocysteine induced the formation of endothelial MPs in vitro and investigated whether this activity is regulated by folate supplementation and the MTHFR polymorphism. We also tried to determine the phenotype of endotheliumreleased microparticles. ® ) purchased from Invitrogen (Paisley, UK), 2 mM of L-glutamine (No. G8540, Sigma-Aldrich, Steinheim, Germany) and antibiotics (50 U/ml penicillin, 50 μ/ml streptomycin, 0.1 mg/ml neomycin, Polfa Tarchomin, Poland). HUVEC from passages 3-4 after overnight serum starvation were used in the study. All of the experiments were performed in duplicate, using nine different primary cell lines.
MATERIALS AND METHODS

Endothelial cell culture
Microparticle formation and isolation
After reaching full confluence, the HUVEC were treated for 24 h with 50 µM DL-Hcy (No. H4628), 5, 15, 50 µM FA (No. F8758) or 50 µM DL-methionine (No. M2768) purchased from Sigma-Aldrich (Steinheim, Germany). The cell culture supernatant was collected and centrifuged for 15 min at 4,500 g. Then the supernatant was centrifuged for 1.5 h at 100,000 g at 4ºC using an ultracentrifuge (Avanti J-30I, Beckman Instruments Inc. Fullerton, USA). Next, the pellets were resuspended in 500 μl of Binding Buffer (BB, Pharmingen TM , BD Bioscience, Bedford, USA) and analysed.
Flow cytometry analysis of microparticles
Microparticle acquisition was performed using a mix of fluorescent beads of various diameters to cover the MP size range from 0.5 to 0.9 μm (Megamix, Biocytex, France) by means of the FACS Calibur instrument (BD Immunocytometry Systems, San Jose, USA). MPs resuspended in BB (50 µl) were incubated in the dark (30 min, 4ºC) with 5 µl of PE-conjugated monoclonal antibody against CD31 (PECAM-1) and 5 µl of FITC-conjugated annexin V (Annexin V-FITC Apoptosis Detection Kit I, Pharmingen TM , BD Bioscience, Heilderberg, Germany) and then centrifuged (1.5 h, 100,000 g, 4ºC) [12] . Afterwards, the pellets were resuspended in 500 μl of PBS, and flow cytometry analysis was performed. The data was analyzed using CellQuest Pro software (BD Immunocytometry Systems, San Jose, USA). The MP number was calculated according to Brodsky et al. [11] . Then the number of MPs shed by the HUVEC was standardized to the number of cells cultured in each flask (kMP).
Hcy analysis
To control the real Hcy concentration under our experimental conditions, High Performance Liquid Chromatography (HPLC) with ultraviolet detection was used (HP 110 Series System, Hewlett-Packard, Waldbronn, Germany) [15] . The level of Hcy was calculated using calibration standards. 
MTHFR (677C>T) polymorphism analysis
Statistical analysis
The results are presented as the means ± SD. The data was analyzed by the Kruskal-Wallis test and the Mann-Whitney U test, using the Statistica 8.0 PL package (StatSoft, Inc. 2008). P-values lower than 0.05 were considered significant.
RESULTS
Hcy turnover in HUVEC culture
The analysis of Hcy turnover in the cell culture supernatant showed that the concentrations of Hcy changed significantly after treatment with FA (Fig. 1) . The mean concentration of Hcy in the presence of 50 μM of FA significantly decreased, from 48.14 ± 7.84 to 29.62 ± 7.93 μM 
The effect of Hcy and Met on MP formation in HUVEC
The flow cytometry analysis showed that HUVEC formed MPs in vitro under the control conditions (Fig. 2) . Stimulation of HUVEC with Hcy significantly induced MP formation when compared to the control conditions: 3,551 ± 620 vs 2,270 ± 657 kMP (p = 0.02). Moreover, supplementation with FA at concentrations of 5, 15 and 50 μM significantly reduced the MP count in the cell culture supernatant: 345 ± 332; 873 ± 329; and 688 ± 453 kMP (p = 0.03), respectively. The protective effect of FA supplementation was also noticeable in presence of the moderate concentration of Hcy (50 μM): 376 ± 155 vs 670 ± 258 vs 420 ± 193 kMP; p = 0.03. Interestingly, Met treatment did not increase MP formation in the HUVEC, compared to the result obtained under the control conditions (1,665 ± 439 vs 2,270 ± 657 kMP). The protective effect of FA on Hcy-stimulated MP formation was not dose-dependent, and no correlation between the FA concentrations and the MP number was observed: r = -0.4, p = 0.44.
The MTHFR (677C>T) polymorphism and Hcy-induced MP formation in HUVEC
The effect of the MTHFR polymorphism on MP formation was analyzed (Fig.  3) . Three of six cell lines analyzed were heterozygous for the 677C>T polymorphism and three were homozygous (677CC). The MTHFR genotype of the HUVEC altered MP formation after Met loading (50 μM): the heterozygotic (677C>T) HUVEC produced twice as many microparticles per million cells as the homozygotic (677CC) ones: 2,341 ± 1,027 vs 1,015 ± 103kMP (p = 0.001). Surprisingly, the MTHFR 677CC polymorphism did not alter the MP release under control conditions nor in the presence of Hcy (50 μM): p = 0.25 and p = 0.66, respectively (Fig. 3) . A significant increase in MP formation after stimulation with Hcy compared to the results obtained under the control conditions was observed both in heterozygotic (677CT) and homozygotic (677CC) HUVEC: respectively, 1,518 ± 343 vs 2,617 ± 152 kMP (p = 0.02); and 2,982 ± 906 vs 4,399 ± 1,127kMP (p = 0.03). 
DISCUSSION
The formation of endothelial MPs is associated with a pathological state which may lead to tissue factor expression and procoagulant activity [11, 16] . Many studies suggest that endothelial cell-derived MPs have a paracrine role and contribute to the development of endothelial dysfunction in most cardiovascular diseases: CAD, MI, hypertension and congestive heart failure. Moreover, diabetes, end-stage renal failure and pulmonary or venous embolism are strong factors bringing about MP shedding [13, 14, 17] . Our study demonstrated that in moderate concentrations, Hcy stimulates endothelial cells (HUVEC) to MP formation, and that FA prevents HUVEC from MP shedding. We may assume that the MTHFR polymorphism is related to MP formation in HHcy and methionine-loading conditions, and that endothelial cellderived MPs have a diverse phenotype, not only apoptotic.
A possible relationship was previously demonstrated between hyperhomocysteinemia after an oral methionine load and endothelial function in healthy adults and cardiovascular patients [18] . Increased Hcy levels, which are related to ischemic conditions, share similar mechanisms that lead to MP formation as a result of cardiac ischemia, myocardial infarction (MI) and stroke [9, 17, 19] . Moreover, endothelial MP numbers correlate inversely with the flow-mediated vasodilatation response and endothelial-related vasorelaxation [12, 20] . Our findings concur with those showing that circulating MPs promote the development of endothelial dysfunction. The different influences of free radicals on the inter-and intracellular mechanisms of bradykinin-dependent vasodilatation compared to vasodilatation in response to other endotheliumdependent stimuli may be regulated by means of MP release [21] . Usui et al. [22] demonstrated that in healthy volunteers, methionine loading acutely attenuated endothelial functions. Pretreatment with FA did not prevent the rise in homocysteine levels, but prevented the impaired vascular response. Our study confirms that FA is an active protector against endothelial cell dysfunction. We demonstrated that FA prevents HUVEC from MP formation under the control conditions, and that this effect was maintained after stimulation with Hcy. Interestingly, folate activity was not dose-dependent in our model, and the concentrations used were efficient. We supposed that the MTHFR polymorphism is involved in MP formation in endothelial cells; the heterozygotic HUVEC responded more significantly to methionine loading and produced twice as many MPs than homozygotic ones. Our study is in accordance with some previous reports on the role of familial hyperhomocysteinemia in atherosclerosis and endothelial dysfunction [11, 18] . Oral administration of methionine at a dose of 100 mg/kg is usually used to induce moderate hyperhomocysteinemia (~25 μM) in healthy human subjects [7] . In our study, we observed that in vitro administration of Met (50 μM) resulted in moderate concentrations of Hcy (33.42 ± 3.72 μM) in the culture supernatant, and these conditions induced a significant increase in the number of MPs. However, we did not observe a similar relationship in the presence of Hcy alone (50 μM). Our observation is in line with Den Heijer's et al. study, which showed that the postload homocysteine levels had stronger genetic determination than the fasting homocysteine levels [23] . In addition, current data suggests that MP number may be genetically regulated [12] . In our study, most MPs were not annexin V-positive (about 75%), which may suggest that the apoptotic process does not dominate in the HHcy response [10] . Unlike other uremic toxins, Hcy did not influence an increase in apoptotic MP numbers [13] . We might speculate that non-apoptotic MPs have proangiogenic activity or transfer coagulation factors (i.e. tissue factors) [14, 16, 17] . We did not analyze the detailed phenotype of HUVEC-derived MPs and this remains a subject for further study. The mechanism of MP formation after Hcy treatment is not clear, but we can postulate that endothelial cells can manage oxidative stress, and MP shedding is a physiological response to moderate hyperhomocysteinemia. We may conclude that the endothelial function impairment due to HHcy is related to MP shedding, which may involve platelets and other cells like monocytes or vascular cells. The limitations of our study are that we used CD31 as the sole marker for endothelial MPs, and that we did not include other markers of endothelial activation, e.g. tissue factor, E-cadheris or cell adhesion molecules. Secondly, we used a low number of different cell lines and replicates in our experiments, but we may assume that in vitro conditions confirm our results. Thirdly, we did not take into consideration the 677TT genotype, which may have been helpful in confirming the role of Hcy metabolism in MP release. However, in certain cell types, an unfavourable phenotype might be driven directly by heterozygosity.
